At a glance
- Originator Novartis
- Class Antifungals
- Mechanism of Action Squalene monooxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 20 Nov 1995 Discontinued-Preclinical for Mycoses in Switzerland (Unknown route)